Advertisement

Pembrolizumab/Trametinib vs Gemcitabine in Addition to SBRT for Pancreatic Cancer
Posted: 04/01/2022 | By: Melissa E. Fryman, MS

Question 1 of 5

Pancreatic cancer has the lowest 5-year survival rate among all cancers, at __%.

Choose 1